uniQure: FDA grants breakthrough status to uniQure's Huntington's disease therapy
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for Huntington's disease.
Read full article »
uniQure is engaged in the development and commercialization of gene therapies for the treatment of cardiovascular and hemophilia diseases.
Read more